Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 2, 2011, Pages 175-181

  Peng, Nan Jing ^a,b   Liou, Wen Shiung ^a   Liu, Ren Shyan ^b,c   Hu, Chin ^a   Tsay, Daw Guey ^a   Liu, Cheng Bin ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

cancer; FDG; imaging; PET

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EARLY DIAGNOSIS; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SECOND CANCER;

ADULT; CA-125 ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 79955923037     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0872     Document Type: Article

References (28)

1. Rustin G, Tuxen M. Use of CA-125 in follow-up of ovarian cancer. Lancet 1996;348:191.
2. Rustin GJS, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA-125: A North Thames Ovary Group Study. Ann Oncol 1996;7:361.
3. Rustin GJS, Marples M, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054.
4. Crawford SM, Paul J, Reed NS, et al. The prognostic significance of the CA-125 nadir in patients that achieve a CA- 125 response. J Clin Oncol 2004;22:449s.
5. Markman M, Liu PY, Rothenberg ML, et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006;24:1454.
6. Nadal RM, Ojeda BM, Artigas V, et al. Stratification of the normal range of CA-125 after chemotherapy as a predictive factor in carcinoma of the ovary. J Clin Oncol 2006;24:270s.
7. Tanabe H, Katsumata N, Matsumoto K, et al. CA-125 nadir as a prognostic factor in advanced ovarian carcinoma: A retrospective study of 84 patients achieving clinical CR. J Clin Oncol 2006;24:270s.
8. Santillan A, Garg R, Xahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA- 125 levels within normal range. J Clin Oncol 2005;23:9338.
9. Liu PY, Alberts DS, Monk RJ, et al. An early signal of CA- 125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007;25:3615.
10. De Ros V, Mangoni Di Stefano ML, Brunetti A, et al. Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan. Eur J Gynaecol Oncol 1995;16:123.
11. Sun SS, Chen TC, Yen RF, et al. Value of whole body 18Ffluoro- 2-deoxyglusose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001;21:2957.
12. Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]- fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310.
13. Chang WC, Hung YC, Kao CH, et al. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro- 2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma 2002;49:329.
14. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: Role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797.
15. Takekuma M, Maeda M, Ozawa T, et al. Positron emission tomography with 18F-fluora-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005;10:177.
16. Garcia-Velloso MJ, Jurado M, Ceamanos C, et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1396.
17. Picchio M, Sironi S, Messa C, et al. Advanced ovarian carcinoma: Usefulness of [18F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 2003;47:77.
18. Nanni C, Rubello D, Farsad M, et al. 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: A prospective study on forty-one patients. Eur J Surg Oncol 2005;31:792.
19. Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007;105:17.
20. Bristow RE, Del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519.
21. Iagarua AH, Mittraa ES, McDougalla IR, et al. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun 2008;29:1046.
22. Gu P, Pan LL, Wu SQ, et al. CA-125, PET alone, PET/CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and met-analysis. Euro J Radiol 2009;71: 164.
23. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J Clin Oncol 2008;26:2155.
24. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management findings of the National Oncologic PET Registry. J Nucl Med 2008;49:1928.
25. Vasey PA. Management of recurrent epithelial ovarian carcinoma. Aust N Z J Obstetr Gynaecol 2005;45:269.
26. Williams MG, Bandera EV, Demissie K, et al. Synchronous primary ovarian and endometrial cancers. A populationbased assessment of survival. Obstet Gynecol 2009;113:783.
27. Chiang YC, Chen CA, Huang CY, et al. Synchronous primary cancers of the endometrium and ovary. Int J Gynecol Cancer 2008;18:159.
28. Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: Correlation with histologic findings. Radiology 2004;233:433.